MADD and cancer: In work by Kurada et al., the authors show that MADD, a splice variant of IG20, is overexpressed in cancer cells and tissues and can specifically activate MAPKs through Grb2 and Sos1/2 recruitment to grant protection against apoptosis upon tumor necrosis factor-α (TNFα) treatment [9].